Your session is about to expire
← Back to Search
TBio-4101 + Pembrolizumab for Advanced Solid Cancers (STARLING Trial)
STARLING Trial Summary
This trial will investigate a potential new cancer treatment using cells from the patient's own tumor.
STARLING Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTARLING Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.STARLING Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has not responded to standard treatments.I have had a cell therapy or organ transplant before.My organs are functioning well.My heart's pumping ability is reduced.My lung function tests show reduced capacity.I have a tumor that can be measured and sampled for treatment.I have another cancer that is getting worse or was treated in the last 3 years.I have an immune system disorder or am on long-term steroids or other immune-weakening medicines.I am currently infected with a virus such as HIV, hepatitis B or C, syphilis, West Nile virus, HTLV I/II, or CMV.I have stable brain metastases after treatment.I do not have serious heart conditions and am cleared by a cardiologist if over 60.You have had a serious allergic reaction to cyclophosphamide, fludarabine, IL-2, or pembrolizumab in the past.I am on a blood thinner that cannot be stopped or changed.I am fully active or can carry out light work.
- Group 1: Head and Neck Squamous Cell Carcinoma
- Group 2: Non-Small Cell Lung Cancer
- Group 3: Breast Cancer
- Group 4: Colorectal carcinoma
- Group 5: Uveal Melanoma
- Group 6: Cutaneous Melanoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Uveal Melanoma pose any health risks to those affected by it?
"Due to the lack of research around Uveal Melanoma, our team at Power has allocated a score of 1. This is because this trial is still in its early stage with limited data regarding safety and efficacy."
Does this research include elderly participants over the age of eighty-five?
"This clinical trial is open to individuals between 18 and 70 years of age. For minors, there are 123 trials whilst 2494 studies have been designed for elderly patients."
How many individuals are being recruited to participate in this trial?
"Affirmative. Clinicaltrials.gov indicates the commencement of recruitment for this medical trial on January 17th, 2023 and its most recent update was on the 27th of that same month. This study is looking to recruit 30 patients split between two locations."
Are there vacancies left within this clinical experiment?
"This clinical trial, initially posted on January 17th 2023 and last modified roughly ten days later, is currently searching for participants. Patient recruitment information can be found at the aforesaid website."
Who fulfills the criteria for participating in this experiment?
"This trial seeks thirty individuals between the ages 18 and 70 who are suffering from breast cancer. Additional prerequisite criteria include: a metastatic or advanced form of colorectal adenocarcinoma, uveal melanoma that is resistant to standard treatment paths, availability for response assessment in at least one target lesion, an ECOG performance status of 0 or 1, as well as adequate organ function. There may be additional inclusion parameters not mentioned here."
Share this study with friends
Copy Link
Messenger